Missionomics Back to app

Healthcare

Idexx Laboratories, Inc. (IDXX)

Healthcare $44.8B market cap

Data as of July 13, 2026

Environment
70.00
People
78.00
Leadership
75.00

Environment story

IDXX reports that greenhouse gas emissions from its operations are not significant and has developed a GHG reduction strategy with tracking of emissions and energy consumption metrics. However, the company does not disclose absolute Scope 1, 2, or 3 emissions figures or a specific net-zero target year in the provided filings. The company acknowledges operational footprint reduction initiatives but lacks comprehensive decarbonization infrastructure investment disclosure. PFAS regulatory exposure is material, with Maine statute exemptions for veterinary products currently in place but phase-out requirements emerging in multiple states (Minnesota 2032). The company maintains ISO 9001, 14001, and 17025 certifications at key facilities. Without verified emissions data or a credible net-zero target before 2045, the score reflects incomplete environmental commitment rather than substantive operational decarbonization.

Criticisms on file

  • PFAS in products subject to increasing regulatory restriction. Maine statute exemptions for veterinary and FDA/USDA-regulated products currently shield IDXX products from 2032 PFAS ban, but exemptions may not persist. Minnesota PFAS product phase-out begins 2032. EU draft PFAS regulations pending. EPA reporting rule under TSCA requires manufacturers to file PFAS chemical identity, production, imports, use, disposal, and health/environmental effects data.
    Source: IDXX 10-K Risk Factors: PFAS regulatory exposure; Maine statute and regulatory timeline documentation.
  • Chemical regulation compliance complexity. Products subject to EU REACH, RoHS Directive, Biocidal Products Regulation, California Proposition 65 warning requirements, and emerging AI governance. Redesign or reformulation of products may be required; cost and market availability impacts acknowledged but not quantified.
    Source: IDXX 10-K Risk Factors: 'Various U.S. and foreign government regulations'; chemical regulation section.
  • Biologic product manufacturing complexity with environmental and waste implications. Rapid assay, livestock, poultry, water and dairy products incorporate biological materials (antibodies, cells, sera) with inherent variability and product loss risk; recall and environmental disposal costs acknowledged.
    Source: IDXX 10-K Risk Factors: 'Our biologic products are complex and difficult to manufacture.'

Disclosed initiatives

  • Greenhouse Gas Emissions Reduction Strategy
    IDXX has developed and is executing a GHG emissions reduction strategy with tracking and public reporting of environmental impact metrics including GHG emissions and energy consumption.
    Monitoring and disclosure framework in place; operational reductions not quantified.
  • Sustainability Considerations in Product Development
    Integration of sustainability considerations for new product development and design, along with reduction initiatives for plastic and material waste from current products and packaging.
    Preventive approach to product lifecycle; scope and magnitude undisclosed.
  • ISO Environmental Certification
    Manufacturing and distribution facilities certified to ISO 14001 environmental quality standard (Westbrook ME, Scarborough ME, Roswell GA, Memphis TN, Netherlands, Switzerland, France, UK).
    Third-party audit and systematic management system for environmental compliance.
  • Corporate Responsibility Reporting
    Most recent Corporate Responsibility Report informed by Sustainability Accounting Standards Board and Task Force on Climate-Related Financial Disclosures frameworks; available on company website.
    Structured transparency framework; actual emissions and targets not disclosed in 10-K.

Social story

IDXX reports approximately 11,000 regular full-time and part-time employees across ~34 countries as of December 31, 2025, with 59% women and 41% men. The company emphasizes inclusive recruitment, merit-based advancement, executive sponsorship of employee-led communities, and comprehensive well-being programs (mental health, financial coaching, ergonomic support). EEO-1 data is disclosed annually and summarized on the website. Turnover is characterized as 'low and healthy for the sector' with strong engagement survey results; no specific turnover rate provided. No documented union-suppression activities, major strikes, or labor litigation are disclosed in the filings. CEO-to-median-worker pay ratio is not disclosed, preventing full assessment against the 200:1 threshold. Leadership diversity percentages (executive/board) are not explicitly quantified in the provided text, though Board composition shows representation. Supply-chain audits and human-rights hazard disclosures are minimal; no specific cobalt or conflict-minerals policies are disclosed. The social score reflects strong governance of human capital and culture but lacks granular pay-equity and supply-chain ethics transparency.

Criticisms on file

  • CEO-to-median-worker pay ratio not disclosed. Executive compensation is detailed in proxy (NEO compensation table), but median worker pay is not provided, preventing verification against the 200:1 threshold in the scoring rubric.
    Source: IDXX Proxy Statement: Executive compensation tables and CEO pay ratio section (page 120) does not disclose the specific ratio.
  • Leadership diversity metrics not explicitly quantified in filings. Board composition shows multiple directors but gender and racial/ethnic diversity percentages for executive and board leadership are not stated as discrete metrics.
    Source: IDXX Proxy Statement: Director biographies and board composition table; no explicit diversity percentage disclosure.
  • Supply-chain human rights and labor audits minimally disclosed. No specific cobalt, lithium, or conflict-minerals policy is mentioned. Supply-chain labor standards, auditing protocols, and remediation procedures for unmitigated hazards are not detailed in the 10-K or proxy.
    Source: IDXX 10-K Risk Factors: General supply chain risk discussion does not address human-rights due diligence or conflict-minerals policies.

Disclosed initiatives

  • Inclusive Culture and Equal Opportunity
    Policies strictly prohibit employment discrimination; merit-based advancement; executive sponsorship of employee-led communities open to all employees; inclusive recruitment practices; annual EEO-1 data collection and disclosure on company website.
    Formal systems for diversity recruitment and advancement; survey-based engagement monitoring shows strong participation.
  • Comprehensive Well-being and Compensation Programs
    Fair and competitive compensation; comprehensive health and welfare insurance; generous time-off and leave; retirement and financial support; free global mental health counseling; financial coaching for North American employees and families; interactive holistic well-being resources including webinars, ergonomic support, fitness challenges, nutrition programs.
    Strong utilization of programs; benchmarked against market; designed to support overall employee well-being and retention.
  • Flexible Work Arrangements
    Goal to enable managers, teams, and employees to identify most effective work arrangements (100% onsite, remote, or hybrid) to accomplish goals and promote positive workplace environment.
    Supports work-life balance and talent retention; collaborative culture through in-person and virtual events.
  • Leadership Development and Career Growth
    Multiple leadership development programs for new managers, frontline leaders, mid-level leaders, and business leaders; individual development plans; job-related courses and degree programs; in-person and virtual training accessible across geographies and languages.
    Builds internal talent pipeline and capabilities; supports succession planning and career progression.
  • Environmental Health and Safety (EH&S) Management System
    Dedicated EH&S team oversees company-wide safety programs; health and safety training, tools, and resources; processes designed to maintain and improve employee safety, reduce workplace risks, and drive continuous improvement at all locations.
    Systematic approach to workplace safety and occupational health; employee empowerment for safety-first culture.

Governance story

IDXX maintains a single-class share structure with no dual-class voting disparities; all shareholders have one vote per share. Board independence stands at 82% (9 of 11 directors independent as of the 2026 proxy), exceeding the 75% threshold. The Board is classified (three staggered classes) with a declassification amendment (Proposal Four) submitted for shareholder approval at the May 2026 annual meeting. Board leadership structure includes an Independent Non-Executive Board Chair (Lawrence D. Kingsley) who will transition to Independent Lead Director post-2026 meeting, with the Company's President and CEO (Jonathan J. Mazelsky) transitioning to Executive Chair. A planned CEO transition to Michael G. Erickson is announced for May 2026, with documented succession planning. The company has four standing committees (Audit, Compensation and Talent, Governance and Corporate Responsibility, Finance) with strong independence and charter oversight. Lobbying expenditures and PAC contributions are not quantified in the provided filings. No active antitrust, consumer-safety fraud, or SEC consent decrees are disclosed. The company does not sue to block shareholder climate proposals; instead, the Board opposes a shareholder proposal requesting 10% call-right for special meetings (Proposal Six), recommending vote 'AGAINST' while supporting a Board-approved 25% threshold (Proposal Five). Overall governance is strong on independence, committee structure, and succession planning; transparency gaps exist in lobbying/political spending disclosure.

Criticisms on file

  • Lobbying expenditures and PAC contributions not disclosed in 10-K or proxy. No quantification of annual lobbying spend, PAC contributions, or alignment with climate/consumer-protection regulation positions provided.
    Source: IDXX 10-K and Proxy Statement: No lobbying or political contribution disclosure found in provided source documents.
  • Board opposition to shareholder proposal for 10% call-right special meeting threshold. Shareholders (John Chevedden, representing >15 shares since Sept 2022) submitted Proposal Six requesting 10% threshold with no ownership duration requirement. Board recommends vote 'AGAINST,' citing its own approved 25% threshold (Proposal Five) as appropriate governance balance. Proposal Six received 51-72% support at peer companies in 2024 (Jabil, Warner Brothers Discovery, ANSYS, Vertex, DexCom).
    Source: IDXX Proxy Statement, Proposal Six: Shareholder proposal text and Board Statement in Opposition (page 137-138).

Disclosed initiatives

  • Board Declassification Amendment
    Proposal Four submitted to shareholders for May 2026 approval to amend Certificate of Incorporation to declassify the Board, enabling annual election of all directors rather than staggered three-year classes.
    Increases shareholder accountability and governance flexibility; responsive to governance best practices.
  • Shareholder Right to Call Special Meeting (25% Threshold)
    Proposal Five submitted to shareholders for May 2026 approval to amend Certificate of Incorporation to permit shareholders owning at least 25% of outstanding shares continuously for at least one year to call a special meeting of shareholders, subject to additional procedural requirements.
    Enhanced shareholder rights and voice; Board-approved threshold (25%) balances shareholder empowerment with governance stability.
  • CEO and Executive Succession Planning
    Governance and Corporate Responsibility Committee (transitioning to Compensation and Talent Committee for non-CEO successors) reviews annual CEO succession plans prepared by the CEO. Full Board ultimately responsible for ensuring appropriate succession plans for CEO and other executive officers. Board members interact with potential candidates in formal and informal settings. Planned CEO transition announced January 13, 2026, effective May 2026.
    Documented, systematic approach to leadership continuity; transparent timeline communicated to shareholders.
  • Board Independence and Committee Governance
    82% board independence; four standing committees (Audit, Compensation and Talent, Governance and Corporate Responsibility, Finance) with independent members and Board-approved charters. Committees oversee material ESG risks, cyber security, AI governance, legal/ethical conduct, and corporate responsibility.
    Strong oversight structure; committee charters address environmental, social, governance, and emerging risk domains.
  • Director Nomination and Refreshment Process
    Board-approved director nomination criteria emphasize skills matrix, diversity of backgrounds, and competencies (executive leadership, corporate strategy, financial acumen, innovation/R&D, human capital, international business, operations, sustainability, digital, corporate finance). Regular board self-assessments and director education programs in place.
    Systematic talent identification and board renewal; alignment of director qualifications with strategic priorities.
  • Corporate Governance Framework and Code of Ethics
    Corporate Governance Guidelines and Code of Ethics available on company website. Board operates under established governance framework including insider trading policies, anti-hedging/short-sale/pledging policies, and shareholder communication and engagement protocols.
    Formalized governance structure and stakeholder engagement processes.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Idexx Laboratories, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Idexx Laboratories, Inc. in the app for interactive charts and portfolio building.

Open Idexx Laboratories, Inc. in Missionomics

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)

Browse Companies · Methodology · Terms of Service · Privacy Policy · Back to Missionomics